Dr Sheryl Ann Cowan, MD | |
403 W Campbell Rd, Suite 103, Richardson, TX 75080-3465 | |
(972) 235-8311 | |
(872) 235-2663 |
Full Name | Dr Sheryl Ann Cowan |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 36 Years |
Location | 403 W Campbell Rd, Richardson, Texas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164430302 | NPI | - | NPPES |
J0935 | Other | TX | MEDICAL LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | J0935 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Methodist Richardson Medical Center | Richardson, TX | Hospital |
Medical City Plano | Plano, TX | Hospital |
Baylor Scott & White Medical Center Plano | Plano, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Arapaho Village Medical Association | 7012031511 | 3 |
News Archive
Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke.
Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.
No single assessment tool is able to consistently determine driving ability in people with Alzheimer's disease and mild cognitive impairment, a St. Michael's Hospital research review has found.
Using a nuclear medicine technique and molecular imaging to "see" programmed cell loss, the body's normal way of getting rid of unneeded or abnormal cells, may help in early identification of those individuals who are at risk of developing heart failure, say researchers in the April Journal of Nuclear Medicine.
CryoLife, Inc., a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology.
› Verified 1 days ago
Entity Name | Arapaho Village Medical Association |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487771523 PECOS PAC ID: 7012031511 Enrollment ID: O20100907000525 |
News Archive
Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke.
Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.
No single assessment tool is able to consistently determine driving ability in people with Alzheimer's disease and mild cognitive impairment, a St. Michael's Hospital research review has found.
Using a nuclear medicine technique and molecular imaging to "see" programmed cell loss, the body's normal way of getting rid of unneeded or abnormal cells, may help in early identification of those individuals who are at risk of developing heart failure, say researchers in the April Journal of Nuclear Medicine.
CryoLife, Inc., a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sheryl Ann Cowan, MD 403 W Campbell Rd, Suite 103, Richardson, TX 75080-3465 Ph: (972) 235-8311 | Dr Sheryl Ann Cowan, MD 403 W Campbell Rd, Suite 103, Richardson, TX 75080-3465 Ph: (972) 235-8311 |
News Archive
Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke.
Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.
No single assessment tool is able to consistently determine driving ability in people with Alzheimer's disease and mild cognitive impairment, a St. Michael's Hospital research review has found.
Using a nuclear medicine technique and molecular imaging to "see" programmed cell loss, the body's normal way of getting rid of unneeded or abnormal cells, may help in early identification of those individuals who are at risk of developing heart failure, say researchers in the April Journal of Nuclear Medicine.
CryoLife, Inc., a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology.
› Verified 1 days ago
Lawrie Hilton Friedman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 670 N Coit Rd Ste 2355, Richardson, TX 75080 Phone: 972-644-3422 Fax: 972-644-5543 | |
Dr. Ahmad Ghassan Abazid, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 888 S Greenville Ave Ste 304, Richardson, TX 75081 Phone: 469-684-5450 | |
Marium Palur Afzal, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3030 Waterview Pkwy, Richardson, TX 75080 Phone: 972-669-7070 | |
Dr. Antoine Robert Albert, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 S Coit Rd, Ste 317, Richardson, TX 75080 Phone: 972-437-9090 Fax: 972-234-6474 | |
Dr. Linda Shelton Halbrook, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2520 N Central Expy, Suite 100, Richardson, TX 75080 Phone: 972-234-3311 Fax: 972-669-8072 | |
Charles Murray Kasbarian, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 670 W. Arapaho Rd, Suite 6, Richardson, TX 75080 Phone: 972-235-6311 Fax: 972-235-5951 | |
John K Wood, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 970 N Coit Rd Ste 3040, Richardson, TX 75080 Phone: 972-238-8092 Fax: 972-238-8093 |